 IMARA Inc. IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia. We are pleased to receive this important designation from the FDA, which underscores the critical need for innovative new treatment options for patients with rare blood disorders such as beta-thalassemia, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. 